Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Conviction and $20K fine follows "serious and prolonged" offending by former podiatrist

Supagas acquires Heeson Medical

Why digital resilience is becoming critical in aged care

Rapid-response discharge model targets bed block

A Good Cleaning Schedule: Best Practices for Healthcare Facilities

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award

Industrial electricity costs could halve by sharing infrastructure

Epson MD serves meals for CEO CookOff

AI solar smart bins to end Vic fixed-route rubbish runs

Testing Profinet I/O devices without a dedicated PLC

CCEP's $39.7m can line upgrade in Perth increases capacity 40%

Cybersecurity and digitalisation for Zimbabwe platinum mine

ENEOS opens Direct MCH large‍-‍scale demonstration plant in Brisbane

ARENA funds manufacturing of solar construction robots

Lonza bone marrow and cord blood mononuclear cells

GeneTex carrier-free antibodies

Cayman Chemical LipidLaunch Ionizable Lipid LNP Screening Set

Antibodies.com neutrophil marker antibodies

Content from other channels on our network